Zhe-Yi Hu

Zhe-Yi Hu

Auto-generated profile, based on publicly available information

Zhe-Yi Hu

Department of Clinical Pharmacy, College of Pharmacy, University of Tennessee Health Science Center, 881 Madison Ave., Memphis, TN, 38163, USA.

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2015 in Current Drug Metabolism
Verified
Journal Article
Closed access
PDF file
DTDandan Tian
Dandan Tian
ZHZheyi Hu
Zheyi Hu
Cytochromes P450 enzymes, especially CYP3A4, are responsible for metabolizing a broad range of anticancer drugs. Combination therapy is common in patients with cancer, which may cause potential drug drug interactions (DDIs) leading to increased risk of side-effects/toxicity or decreased effectiveness. The review summarizes CYP3A4-mediated DDIs, with anticancer drugs as CYP3A4 substrates or modulators, in clinical trials during cancer therapy and aims to increase clinicians' awareness to take caution to reduce the risk.


4 September 2012 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
ZHZhe-Yi Hu
Zhe-Yi Hu
SLS. Casey Laizure
S. Casey Laizure
BMBernd Meibohm
Bernd Meibohm
VHVanessa L. Herring
Vanessa L. Herring
RPRobert B. Parker
Robert B. Parker


20 April 2014 in Rapid Communications in Mass Spectrometry
Verified
Journal Article
Closed access
PDF file
ZHZhe‐Yi Hu
Zhe‐Yi Hu
SLS. Casey Laizure
S. Casey Laizure
VHVanessa L. Herring
Vanessa L. Herring
RPRobert B. Parker
Robert B. Parker

1 August 2012 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
ZHZhe-Yi Hu
Zhe-Yi Hu
RPRobert B. Parker
Robert B. Parker
SLS. Casey Laizure
S. Casey Laizure
The in vivo drug-drug interaction (DDI) risks associated with cytochrome P450 inhibitors that have circulating inhibitory metabolites cannot be accurately predicted by conventional in vitro-based methods. A novel approach, in vivo information-guided prediction (IVIP), was recently introduced for CYP3A- and CYP2D6-mediated DDIs. This technique should be applicable to the prediction of DDIs involving other important cytochrome P450 metabolic pathways. Therefore, the aims of this study were to extend the IVIP approach to CYP2C9-mediated DDIs and evaluate the IVIP approach for predicting DDIs associated with inhibitory metabolites. The analysis was based on data from reported DDIs in the literature. The IVIP approach was modified and extended to CYP2C9-mediated DDIs. Thereafter, the IVIP approach was evaluated for predicting the DDI risks of various inhibitors with inhibitory metabolites. Although the data on CYP2C9-mediated DDIs were limited compared with those for CYP3A- and CYP2D6-mediated DDIs, the modified IVIP approach successfully predicted CYP2C9-mediated DDIs. For the external validation set, the prediction accuracy for area under the plasma concentration-time curve (AUC) ratios ranged from 70 to 125%. The accuracy (75–128%) of the IVIP approach in predicting DDI risks of inhibitors with circulating inhibitory metabolites was more accurate than in vitro-based methods (28–805%). The IVIP model accommodates important confounding factors in the prediction of DDIs, which are difficult to handle using in vitro-based methods. In conclusion, the IVIP approach could be used to predict CYP2C9-mediated DDIs and is easily modified to incorporate the additive effect of circulating inhibitory metabolites.